Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 2429Neoplasms 1840Carcinoma, Non-Small-Cell Lung 1615Prostatic Neoplasms 1309Colorectal Neoplasms 1147Lung Neoplasms 991Neoplasm Metastasis 836Multiple Myeloma 801Leukemia, Myeloid, Acute 777Ovarian Neoplasms 682Pancreatic Neoplasms 667Melanoma 667Squamous Cell Carcinoma of Head and Neck 592Recurrence 568Carcinoma, Hepatocellular 568Brain Neoplasms 529Glioblastoma 519Stomach Neoplasms 504Head and Neck Neoplasms 503Triple Negative Breast Neoplasms 472Lymphoma 462Uterine Cervical Neoplasms 454Carcinoma, Renal Cell 429Precursor Cell Lymphoblastic Leukemia-Lymphoma 419Lymphoma, Non-Hodgkin 392Endometrial Neoplasms 385Sarcoma 370Lymphoma, Follicular 358Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 355

Interventions

Gemcitabine 3130-nm albumin-bound paclitaxel 2Taxes 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Metastatic Pancreatic Ductal Adenocarcinoma × 1 year × Clear all
NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2 Recruiting
61 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT06646055 2026-03-09

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Akeso

Phase 1/2 Active not recruiting
110 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT05630183 2025-11-13

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Agenus Inc.

Phase 2 Active not recruiting
81 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡